The investment represented an opportunity to acquire a class-A, fully-occupied asset in an off-market transaction with compelling supply/demand fundamentals.
The property is in New Jersey’s Somerset submarket, with immediate access to I-287 and is situated across the street for a 1 million sf+ distribution park and less than an hour from Manhattan. Somerset is one of New Jersey’s primary distribution points for commerce, featuring access to freeway, port, and rail traffic. The property contains one user, the largest privately held generic drug developer in the U.S with expected revenues of $380M in 2021.